Clinical trials: Atherosclerotic Lesion(s)
Coronary Artery Disease
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of…
- Trial name
- EVOLVE48 (NCT03350542)
- Testing
- SYNERGY 48 mm
- Where
- 15 sites in United States, Latvia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Atherosclerotic Lesion(s)
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound (IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) in the treatment of subjects…
- Trial name
- EVOLVE II QCA (NCT01787799)
- Testing
- SYNERGY
- Where
- 13 sites in Australia, Japan and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Cardiovascular Diseases
SYNERGY China: Assess SYNERGY Stent in China
Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.
- Trial name
- NCT02499692
- Testing
- SYNERGYTM Coronary Stent System
- Where
- 8 sites in China
- Volunteers
- 103 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The EVOLVE China Clinical Trial
The purpose of this study is to assess the safety and effectiveness of the SYNERGY™ Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary…
- Trial name
- EVOLVE-CHINA (NCT01966159)
- Testing
- SYNERGY Investigational Device, PE Plus Investigational Device
- Where
- 14 sites in China
- Volunteers
- 412 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis
PE PREMIER CHINA CLINICAL TRIAL
PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT02230254
- Testing
- Percutaneous coronary intervention PROMUS PREMIER
- Volunteers
- 101 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Coronary Artery Disease
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT01703000
- Testing
- Percutaneous coronary intervention (NG PROMUS)
- Where
- 9 sites in Australia, New Zealand and 1 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by…
- Trial name
- NCT01665053
- Testing
- PROMUS Element Plus, SYNERGY
- Where
- 126 sites in United States, Australia and 14 more
- Volunteers
- 1,684 people
- Sponsor
- Boston Scientific Corporation